The FDA has approved the combination of pembrolizumab, pemetrexed, and carboplatin for the first-line treatment of metastatic non-squamous NSCLC, regardless of PD-L1 expression (11). The gene discussed is CD274; the disease is non-small cell lung carcinoma.